Complications and Practice Variation in the Use of Peripherally Inserted Central Venous Catheters in People With Cystic Fibrosis
Alex H. Gifford(Rainbow Babies & Children's Hospital), Jonathan B. Zuckerman(Maine Medical Center), Patrick A. Flume(Medical University of South Carolina), Deepika Polineni(Washington University in St. Louis), Alexandra C. Hinton(Maine Medical Center), Samya Z. Nasr(University of Michigan), F. Lee Lucas(Maine Medical Center), Joel Mermis(University of Kansas), Shijing Jia(University of Michigan), Rebecca Dezube(Johns Hopkins University), Hossein Sadeghi(Columbia University Irving Medical Center), Thomas Lahiri(University of Vermont Medical Center), Emily DiMango(Columbia University Irving Medical Center), Elliott C. Dasenbrook(Cleveland Clinic), Edith T. Zemanick(Children's Hospital Colorado), Charlotte C. Tenebäck(University of Vermont Medical Center), Natalie E. West(Johns Hopkins University)
Cited by 5
Related Papers
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>
|New England Journal of Medicine|2015|1.6k
Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by <i>Mycobacterium avium</i> Complex (CONVERT). A Prospective, Open-Label, Randomized Study
|American Journal of Respiratory and Critical Care Medicine|2018|343
Persistent Methicillin-resistant <i>Staphylococcus aureus</i> and Rate of FEV1 Decline in Cystic Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2008|322